Government Slashes Prices Of 137 Anti-Cancer Drugs: The central government has taken a major step toward reducing the cost of ...

Summit Therapeutics SMMT is working to expand ivonescimab’s growth potential beyond non-small cell lung cancer (NSCLC), its lead development area. The company is advancing the investigational drug ...

A case report found enlarging pulmonary cavities despite regressing solid components and thinning walls, complicating ...

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food and Drug Administration ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination ...

The issue of education and treatment of breast cancer is back in the spotlight, especially during Breast Cancer Awareness ...

Colorectal Cancer Trials to Watch at ESMO 2026 / cancer, cancer care, Cancer research, cancer treatment, chemotherapy, clinical trials, colorectal cancer, ...

A 2026 review finds that TCR-engineered T cells have entered early clinical testing for hepatocellular carcinoma, but safety, antigen heterogeneity and immune suppression remain major barriers.

Ivonescimab was invented by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies ...

PD-1 bispecific antibodies combine checkpoint blockade with CTLA-4 or VEGF targeting. Can one engineered molecule offer ...

South Korean biosimilar maker Celltrion is pushing beyond hospital tenders into European pharmacies, aiming to carry its ...

Roche announced new Phase III data for investigational fenebrutinib in multiple sclerosis (MS), demonstrating reduced markers of chronic brain inflammation as well as more comprehensive disease ...